Kawamura Y, Shimomura A, Shimizu C. Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy? J Clin Oncol 2021 Jul 6:JCO2101174. doi: 10.1200/JCO.21.01174.
PMID: 34228507